ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX), a biotechnology company focused on gene therapy treatments, is planning a $125 million underwritten public offering of its common stock, the company announced today. The completion and terms of the offering are subject to market conditions, and there is no guarantee of when or if the offering will be finalized.
The company also intends to provide a 30-day option for underwriters to purchase up to an additional 15% of the number of shares sold during the offering. Morgan Stanley, Goldman Sachs & Co (NYSE:GS). LLC, Barclays, and Stifel have been appointed as joint book-running managers for the offering.
The shares are being offered pursuant to an automatically effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on December 30, 2022. Details regarding the offering will be available in a preliminary prospectus supplement filed with the SEC. Interested parties can obtain copies of this document from the book-running managers once available.
REGENXBIO, established in 2009, has been a pioneer in developing AAV Therapeutics, a novel class of gene therapy medicines. Its pipeline includes treatments for retinal and rare diseases, with notable collaborations such as the development of ABBV-RGX-314 with AbbVie (NYSE:ABBV). ZOLGENSMA, a treatment for spinal muscular atrophy in children, is one of the products created using REGENXBIO's AAV Therapeutic platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.